|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
SLFN12 may reduce TNBC aggressiveness and improve survival in part by a post-transcriptional decrease in ZEB1 that promotes TNBC cancer stem cell differentiation.
|
31838790 |
2019 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Optimization of PDE3A Modulators for SLFN12-Dependent Cancer Cell Killing.
|
31749907 |
2019 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
SLFN12 may reduce TNBC aggressiveness and improve survival in part by a post-transcriptional decrease in ZEB1 that promotes TNBC cancer stem cell differentiation.
|
31838790 |
2019 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Optimization of PDE3A Modulators for SLFN12-Dependent Cancer Cell Killing.
|
31749907 |
2019 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Understanding how SLFN12 influences prostatic epithelial differentiation may ultimately identify targets to influence the phenotype of prostatic malignancy.
|
24768141 |
2014 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Understanding how SLFN12 influences prostatic epithelial differentiation may ultimately identify targets to influence the phenotype of prostatic malignancy.
|
24768141 |
2014 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
The present investigation was undertaken to examine whether Slfn-3 plays a role in regulating differentiation of FOLFOX-resistant (5-fluorouracil + oxaliplatin) colon cancer cells that are highly enriched in cancer stem cells (CSCs).
|
21596996 |
2011 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
The present investigation was undertaken to examine whether Slfn-3 plays a role in regulating differentiation of FOLFOX-resistant (5-fluorouracil + oxaliplatin) colon cancer cells that are highly enriched in cancer stem cells (CSCs).
|
21596996 |
2011 |
|
Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
SLFN12 expression was lower in TNBC tumors and correlated with survival.
|
31838790 |
2019 |
|
Tumor Cell Invasion
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
In MDA-MB-231 cells, AdSLFN12 reduced invasion, promoted cell cycle arrest, increased E-cadherin promoter activity, mRNA, and protein, and reduced vimentin expression and protein.SLFN12 knockdown increased vimentin.
|
31838790 |
2019 |
|
Triple Negative Breast Neoplasms
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
SLFN12 overexpression reduced TNBC MDA-MB-231, BT549, and Hs578T proliferation.
|
31838790 |
2019 |
|
Triple-Negative Breast Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
SLFN12 overexpression reduced TNBC MDA-MB-231, BT549, and Hs578T proliferation.
|
31838790 |
2019 |
|
Multiple Sclerosis, Relapsing-Remitting
|
0.010 |
Biomarker
|
disease |
BEFREE |
Two of the genes that showed both methylation and expression differences, NINJ2 and SLFN12, have not previously been implicated in MS. SLFN12 is a particularly compelling target of further research, as this gene is known to be down-regulated during T cell activation and up-regulated by type I interferons (IFNs), which are used to treat MS.
|
30379917 |
2018 |
|
Gastrointestinal Stromal Tumors
|
0.010 |
Biomarker
|
group |
BEFREE |
Our results suggest a role for PDE3A during ICC development and open novel perspectives for PDE3A in targeted GIST therapy, on one hand by the synergism between imatinib and cilostazol, a PDE3 inhibitor already in clinical use for other indications, and, on the other hand, by the neomorphic, druggable, PDE3A-SLFN12 cytotoxic interplay.
|
28454120 |
2017 |
|
Sezary Syndrome
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Novel TBL1XR1, EPHA7 and SLFN12 mutations in a Sezary syndrome patient discovered by whole exome sequencing.
|
24689486 |
2014 |
|
Short Bowel Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
Understanding how Slfn3 works may identify targets to promote enterocytic differentiation and maintain mucosal function in vivo, facilitating enteral nutrition and improving survival in patients with mucosal atrophy or short gut syndrome.
|
24244554 |
2013 |
|
Mucosal atrophy
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Understanding how Slfn3 works may identify targets to promote enterocytic differentiation and maintain mucosal function in vivo, facilitating enteral nutrition and improving survival in patients with mucosal atrophy or short gut syndrome.
|
24244554 |
2013 |
|
Roux-en-y Anastomosis Site
|
0.010 |
Biomarker
|
disease |
BEFREE |
Endogenous Slfn3 was reduced in atrophic mucosa from a blind-end Roux-en-Y anastomosis in parallel with differentiation marker expression together with AKT and p38 signaling.
|
24244554 |
2013 |
|
Malignant tumor of colon
|
0.010 |
Biomarker
|
disease |
BEFREE |
Transfection of Slfn-3 in FOLFOX-resistant colon cancer HCT-116 cells resulted in increase of alkaline phosphatase activity, a marker of intestinal differentiation.
|
21596996 |
2011 |
|
Colon Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Transfection of Slfn-3 in FOLFOX-resistant colon cancer HCT-116 cells resulted in increase of alkaline phosphatase activity, a marker of intestinal differentiation.
|
21596996 |
2011 |